164455-08-7

Basic information

• Product Name: (+)-(3aR)-N¹-benzylnoreseromethole
• Synonyms: (+)-(3aR)-N¹-benzylnoreseromethole
• CAS NO: 164455-08-7
• Molecular Weight: 308.423
• Mol File: 164455-08-7.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: (+)-(3aR)-N¹-benzylnoreseromethole(CAS DataBase Reference)
• NIST Chemistry Reference: (+)-(3aR)-N¹-benzylnoreseromethole(164455-08-7)
• EPA Substance Registry System: (+)-(3aR)-N¹-benzylnoreseromethole(164455-08-7)

Safety Data

• Hazardous Substances Data: 164455-08-7(Hazardous Substances Data)

Upstream product

• 153880-70-7 2-bromo-N-(4-ethoxy-phenyl)-N-methyl-propionamide 
• 116707-99-4 1,3-dimethyl-5-methoxyindolin-2-one 
• 1010-68-0 1,3-dimethyl-5-hydroxyoxindole 
• 100-39-0 benzyl bromide 
• 2291-51-2 (5-methoxy-1,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-3-yl)acetonitrile 
• 3154-18-5 N-methyl-p-phenetidine 

Downstream Products

• 164455-12-3 (+)-(3aR)-N¹-benzylnoreseroline p-cymylcarbamate 
• 164455-11-2 (+)-(3aR)-N¹-benzylnoreseroline o-tolylcarbamate 
• 164455-10-1 (+)-(3aR)-N¹-benzylnoreseroline methylcarbamate 
• 159652-56-9 (+)-(3aR)-N¹-benzylnoreseroline phenylcarbamate 
• 164455-09-8 (+)-(3aR)-N¹-benzylnoreseroline 

Relevant articles and documents

Racemic N1-norphenserine and its enantiomers: Unpredicted inhibition of human acetyl- and butyrylcholinesterase and β-amyloid precursor protein in vitro

The optically pure enantiomers of N1-norphenserine (15, 16) were synthesized and its racemate 17 was prepared by mixing equal parts of each enantiomer. (-)-N1-Norphenserine (15) was prepared by partial synthesis initiated from the natural product, (-)-physostigmine (1). (+)-N 1-Norphenserine (16) was prepared by total synthesis using the Julian oxindole route, with modifications. The in vitro inhibitory activities of 15-17 were quantified against human erythrocyte AChE and plasma BChE as well as against human neuroblastoma cell β-amyloid precursor protein secretion in cell culture. All were active. Racemic compound (17) with a high AChE and β-amyloid precursor protein inhibitory action may warrant further assessment in Alzheimer's disease models.